ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer.

The global Acquired hemophilia A Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Acquired hemophilia A Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acquired hemophilia A Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Acquired hemophilia A Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Acquired hemophilia A Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Sanofi
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
200IU
250IU

Segment by Application
Hospital
Pharmacy